Delivery Order SPE2DB20D9156-SPE2DB25FH27N

Award Date 3/17/25
Potential Completion Date 4/7/25
Potential Value $4.2K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order award made by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $4,165.86 contract is for the delivery of NEXPLANON 68 MG IMPLANTS, a contraceptive product, with a period of performance through April 24, 2025. DMS Pharmaceutical Group Inc. holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the DLA to issue firm...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $2,082.93 contract is for the delivery of NEXPLANON 68 MG IMPLANTS, a contraceptive implant, with a period of performance through January 30, 2025. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue delivery orders...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $2,144.07, is for the delivery of NEXPLANON 68 MG IMPLANTS, a prescription contraceptive device, with a completion date of January 2, 2025. DMS Pharmaceutical Group Inc. holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program,...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $4,165.86 contract is for the delivery of NEXPLANON 68 MG IMPLANTS, a contraceptive product, with a performance period ending on January 29, 2025. DMS Pharmaceutical Group Inc. holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $4,165.86 contract is for the delivery of 4,567,229,402 units of NEXPLANON 68 MG IMPLANTS, a contraceptive device, with a period of performance through March 3, 2025. DMS Pharmaceutical Group Inc. holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which allows the...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $6,943.10 contract is for the delivery of NEXPLANON 68 MG IMPLANTS, a specialized contraceptive product, with a period of performance through March 18, 2025. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program,...
This is a firm fixed-price delivery order awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, by the Defense Logistics Agency (DLA). The $4,786.18 contract is for the supply of NEXPLANON 68 MG IMPLANTS, a contraceptive product, with an ultimate completion date of October 5, 2023. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue delivery...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $4,165.86 contract is for the delivery of NEXPLANON 68 MG IMPLANTS, a specialized pharmaceutical product, with a period of performance through April 28, 2025. DMS Pharmaceutical Group Inc. holds a significant $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $6,943.10 contract is for the delivery of NEXPLANON 68 MG IMPLANTS, a contraceptive product, with a completion date of February 7, 2025. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $6,837.40 contract is for the delivery of NEXPLANON 68 MG IMPLANTS, a type of contraceptive implant, with a completion date of October 18, 2023. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables...
  • SPE2DB20D9156
    Indefinite Delivery Contract
  • SPE2DB20D9156-SPE2DB25FH27N
    Delivery Order

This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $4,165.86 contract is for the delivery of NEXPLANON 68 MG IMPLANTS, a branded contraceptive medication, with a performance period ending on April 7, 2025.

DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue delivery orders for a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables. This specific delivery order is not associated with any set-aside designation.

Generated 6/16/25, 10:43 AM